Autres langues Jasper Therapeutics, Inc.

Actions

JSPR

US4718712023

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/06/2024			Varia. 5j.	Varia. 1 janv.
21,3 ^USD	-5,33%		-12,42%	+169,96%

19/06	Jasper Therapeutics, Inc. annonce des changements au sein de son conseil d'administration	CI
14/06	Jasper Therapeutics, Inc. présente les données de l'étude préclinique sur le briquilimab au congrès hybride de l'EHA 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors	19/06
Jasper Therapeutics, Inc. Announces Board Changes	19/06
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit	17/06
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress	17/06
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress	14/06
Jasper Therapeutics, Inc. Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress	14/06
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024	31/05
Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024	31/05
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference	29/05
Jasper Therapeutics : Corporate Presentation May 2024	20/05
Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments	14/05
Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	13/05
Jasper Therapeutics : Corporate Presentation May 2024	13/05
Jasper Therapeutics Announces Briquilimab Development Program in Asthma	13/05
Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients	13/05
Jasper Therapeutics to Present at Upcoming Investor Conferences in May	07/05
Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05
Certain Common Stock of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Jasper Therapeutics, Inc.

Actions

JSPR

US4718712023

Autres langues

Filtres